I'd dare say they are, but it's a matter of whether their client's meet eligibility criteria, and I'd dare say the requirement to have had 2 failed therapies certainly reduces the field.
Ann: Phase 1 onCARlytics Trial Doses First Intravenous Patient, page-89
Add to My Watchlist
What is My Watchlist?
 (20min delay)
|
|||||
|
Last
1.5¢ |
Change
0.000(0.00%) |
Mkt cap ! $112.0M | |||
| Open | High | Low | Value | Volume |
| 1.5¢ | 1.5¢ | 1.4¢ | $106.6K | 7.454M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 73 | 14285652 | 1.4¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 1.5¢ | 8660871 | 30 |
View Market Depth
| Last trade - 16.10pm 16/06/2025 (20 minute delay) ? |
| IMU (ASX) Chart |